Galmed Pharmaceutica (GLMD)

$0.56 +0.05 (9.12%)
Market Cap 3.39M
Revenue (ttm) 0.00
Net Income (ttm) -10.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 294,100
Avg Vol 933,140
Day's Range N/A - N/A
Shares Out 6.60M
Stochastic %K 55%
Beta 0.74
Analysts Hold
Price Target $12.00

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Stu...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 693 8448
Fax: 972 3 693 8447
Address:
16 Abba Hillel Road, Ramat Gan, Israel
Vermont512
Vermont512 Aug. 19 at 11:34 AM
$GLMD Are we leaving today? ㅎㅎ
0 · Reply
focafoca99
focafoca99 Aug. 19 at 11:23 AM
$GLMD shared first-in-human proof-of-concept results for Colospan's intraoperative tissue assessment tech.
0 · Reply
VolcanicTrades
VolcanicTrades Aug. 19 at 11:11 AM
$CATX $11 and $18 price targets the past couple days. $GLMD with another great PR Monday also
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Aug. 19 at 10:47 AM
$CISS 1.44M float - 2.70$ $GLMD 1M float - 4.60$ Just like $RCON & $CXAI yesterday, these 2 could be running today. Watch for dips.
0 · Reply
npcpaperboy
npcpaperboy Aug. 19 at 10:24 AM
$GLMD ride the split
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Aug. 19 at 7:28 AM
$GLMD Galmed Pharmaceuticals Ltd. (GLMD) is executing a 1-for-8 reverse stock split effective today, August 19, 2026. The estimated new tradable float for GLMD is ~1.04 million shares.
0 · Reply
Lowlyme
Lowlyme Aug. 19 at 1:49 AM
$GLMD Bye the way Allen. Still looking for my balls.
0 · Reply
Lowlyme
Lowlyme Aug. 19 at 1:41 AM
$GLMD Hmm. Didn't know that particular rule.. Not an expert.. But I'm sure our CEO is aware of it. Personally. just would like my 20$ grand back.. Allen. Only a weeks draw for you.. Want my bank routing number?
0 · Reply
never_chase
never_chase Aug. 18 at 8:32 PM
$GLMD How come it s up 9% one day before the RS ? Usually it s a bad thing. Anyone ?
1 · Reply
TwongStocks
TwongStocks Aug. 18 at 8:15 PM
Two NASDAQ stocks with reverse splits on Wednesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Wednesday morning. $CISS 1 for 40. Will reduce outstanding shares from approx 57.6m to approx 1.44m. $GLMD 1 for 8. Will reduce outstanding shares from approx 8.33m to approx 1.04m.
0 · Reply
Latest News on GLMD
Colospan completes feasibility study of new assesment platform

2026-08-19T11:15:09.000Z - 24 minutes ago

Colospan completes feasibility study of new assesment platform

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Aug 19, 2026, 7:00 AM EDT - 39 minutes ago

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Galmed trading halted, news pending

2026-08-18T23:50:11.000Z - 11 hours ago

Galmed trading halted, news pending

Galmed reports results from study of a combination of Aramchol and Xtandi

2026-08-17T13:20:27.000Z - 1 day ago

Galmed reports results from study of a combination of Aramchol and Xtandi

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Aug 17, 2026, 9:15 AM EDT - 1 day ago

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s

2026-07-28T11:16:10.000Z - 22 days ago

Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

Jul 28, 2026, 7:00 AM EDT - 22 days ago

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

Galmed announces development of novel LNP cardiac targeted Aramchol formulation

2026-07-16T11:45:37.000Z - 4 weeks ago

Galmed announces development of novel LNP cardiac targeted Aramchol formulation

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Jul 16, 2026, 7:30 AM EDT - 4 weeks ago

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Galmed announces restructured acquisition terms for Colospan

2026-06-22T11:27:49.000Z - 2 months ago

Galmed announces restructured acquisition terms for Colospan

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

Jun 22, 2026, 7:00 AM EDT - 2 months ago

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

Galmed to acquire Colospan in cash and stock deal

2026-06-08T12:27:05.000Z - 2 months ago

Galmed to acquire Colospan in cash and stock deal

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Jun 8, 2026, 8:10 AM EDT - 2 months ago

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

2026-06-02T12:19:17.000Z - 2 months ago

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

2026-06-02T12:18:29.000Z - 2 months ago

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Jun 2, 2026, 7:30 AM EDT - 2 months ago

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Galmed reports results from first-in-man PK study of Aramchol Meglumine

2026-05-14T11:53:04.000Z - 3 months ago

Galmed reports results from first-in-man PK study of Aramchol Meglumine

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

May 14, 2026, 7:30 AM EDT - 3 months ago

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform

2026-05-07T07:22:50.000Z - 3 months ago

Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

May 6, 2026, 7:30 AM EDT - 3 months ago

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Galmed announces research agreement with Ramot at Tel Aviv University

2026-04-14T11:43:26.000Z - 4 months ago

Galmed announces research agreement with Ramot at Tel Aviv University

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Apr 14, 2026, 7:30 AM EDT - 4 months ago

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?

2026-04-09T12:36:46.000Z - 4 months ago

Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?

Galmed announces development of brain penetrating formulation of Aramchol

2026-04-09T12:02:39.000Z - 4 months ago

Galmed announces development of brain penetrating formulation of Aramchol

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Apr 9, 2026, 7:30 AM EDT - 4 months ago

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 31, 2026, 4:15 PM EDT - 5 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jan 30, 2026, 4:15 PM EST - 7 months ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 8, 2025, 8:30 AM EST - 9 months ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed granted new Use Patent related to lead compound Aramchol

2025-12-04T13:35:34.000Z - 9 months ago

Galmed granted new Use Patent related to lead compound Aramchol

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 4, 2025, 8:30 AM EST - 9 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed issues CEO letter to shareholders

2025-12-01T13:40:19.000Z - 9 months ago

Galmed issues CEO letter to shareholders

Galmed Issues CEO Letter to Shareholders

Dec 1, 2025, 8:30 AM EST - 9 months ago

Galmed Issues CEO Letter to Shareholders

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26, 2025, 8:30 AM EST - 9 months ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine

2025-11-18T14:47:44.000Z - 9 months ago

Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 18, 2025, 8:30 AM EST - 9 months ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers

2025-11-17T13:41:03.000Z - 9 months ago

Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Nov 17, 2025, 8:30 AM EST - 9 months ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed approves digital asset management strategy

2025-08-25T11:35:22.000Z - 1 year ago

Galmed approves digital asset management strategy

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Aug 25, 2025, 7:30 AM EDT - 1 year ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 27, 2025, 8:00 AM EDT - 1 year ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

May 6, 2025, 7:30 AM EDT - 1 year ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Apr 2, 2025, 4:10 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Mar 20, 2025, 8:55 AM EDT - 1 year ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 25, 2024, 8:00 AM EDT - 2 years ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Vermont512
Vermont512 Aug. 19 at 11:34 AM
$GLMD Are we leaving today? ㅎㅎ
0 · Reply
focafoca99
focafoca99 Aug. 19 at 11:23 AM
$GLMD shared first-in-human proof-of-concept results for Colospan's intraoperative tissue assessment tech.
0 · Reply
VolcanicTrades
VolcanicTrades Aug. 19 at 11:11 AM
$CATX $11 and $18 price targets the past couple days. $GLMD with another great PR Monday also
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Aug. 19 at 10:47 AM
$CISS 1.44M float - 2.70$ $GLMD 1M float - 4.60$ Just like $RCON & $CXAI yesterday, these 2 could be running today. Watch for dips.
0 · Reply
npcpaperboy
npcpaperboy Aug. 19 at 10:24 AM
$GLMD ride the split
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Aug. 19 at 7:28 AM
$GLMD Galmed Pharmaceuticals Ltd. (GLMD) is executing a 1-for-8 reverse stock split effective today, August 19, 2026. The estimated new tradable float for GLMD is ~1.04 million shares.
0 · Reply
Lowlyme
Lowlyme Aug. 19 at 1:49 AM
$GLMD Bye the way Allen. Still looking for my balls.
0 · Reply
Lowlyme
Lowlyme Aug. 19 at 1:41 AM
$GLMD Hmm. Didn't know that particular rule.. Not an expert.. But I'm sure our CEO is aware of it. Personally. just would like my 20$ grand back.. Allen. Only a weeks draw for you.. Want my bank routing number?
0 · Reply
never_chase
never_chase Aug. 18 at 8:32 PM
$GLMD How come it s up 9% one day before the RS ? Usually it s a bad thing. Anyone ?
1 · Reply
TwongStocks
TwongStocks Aug. 18 at 8:15 PM
Two NASDAQ stocks with reverse splits on Wednesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Wednesday morning. $CISS 1 for 40. Will reduce outstanding shares from approx 57.6m to approx 1.44m. $GLMD 1 for 8. Will reduce outstanding shares from approx 8.33m to approx 1.04m.
0 · Reply
edmark1994
edmark1994 Aug. 18 at 7:14 PM
$GLMD in case you wonder why its up There is Rotation of investments from the tech sector witch is pretty Exhausted right now to the Medical Sector and others
0 · Reply
edmark1994
edmark1994 Aug. 18 at 6:59 PM
$GLMD $SDOT movment style would be nice
0 · Reply
Shakattack31
Shakattack31 Aug. 18 at 6:42 PM
$GLMD wtf
1 · Reply
R_NW
R_NW Aug. 18 at 5:18 PM
$PFSA $WETO $IPST $PFSA $CAST Is $GLMD going to have the same reaction, it is having a reverse split tomorrow and has been suppressed by the stock price despite good news? 10:14 AM
0 · Reply
Shakattack31
Shakattack31 Aug. 18 at 3:53 PM
$GLMD why do people buy this share before the RS ?
2 · Reply
Mile111
Mile111 Aug. 18 at 3:06 PM
$GLMD i sell now all my shares good luck for all they Not sell we see again when this going again under 1 Dollar 🤣🤣🤣🤣👍🤦
1 · Reply
YaKnowImRight
YaKnowImRight Aug. 18 at 3:01 PM
$GLMD One reason why the RS is happening now despite the 180-day extension. Given their recent track record of RS every other year, it makes some sense: "Under updated Nasdaq Listing Rules, a company that falls back below $1.00 within one year of a reverse split faces immediate delisting proceedings without an automatic grace period."
1 · Reply
edmark1994
edmark1994 Aug. 18 at 2:26 PM
$GLMD be careful who holds
1 · Reply
Mile111
Mile111 Aug. 18 at 2:20 PM
$GLMD edmark Not you buy for 0.47 tomorrow 4 Dollar IS your buy 🤣🤣🤣🤣
0 · Reply
edmark1994
edmark1994 Aug. 18 at 2:06 PM
$GLMD Well im in at 0.47$ lets see what it brings.. upcoming days
0 · Reply
Shakattack31
Shakattack31 Aug. 18 at 1:56 PM
$GLMD anyone know when the RS is happening today ?
1 · Reply
Mile111
Mile111 Aug. 18 at 1:37 PM
$GLMD ka 1954 they will Take all the Money from Investors 😵‍💫
0 · Reply